We’re excited to share that Cairn Diagnostics will attend the 85th Scientific Sessions of the American Diabetes Association (ADA), which will take place June 20–23, 2025, at the McCormick Place Convention Center in Chicago. This world-renowned event brings together the brightest minds in diabetes research, care, and innovation, and we’re proud to be a part…
The countdown to Digestive Disease Week (DDW) 2025 has begun, and we at Cairn Diagnostics couldn’t be more excited to attend this premier gastroenterology, hepatology, and digestive health event. As a leader in innovative breath testing solutions, we are eager to connect, collaborate, and share how our Gastric Emptying Breath Test (GEBT) transforms how clinicians…
In ancient times carefully placed stacks of stones would be created as a way of noting a specific place or as trail markers to ensure travelers marked their course and didn’t lose their way. They were called “cairns”. Kerry Bush, the President and Chief Operating Officer for Cairn Diagnostics, chose this name for his company…
With the holidays around the corner, many people with digestive issues are experiencing increased levels of stress when thinking of eating a multi-course meal at the family holiday table. It can be rather upsetting to commit to invitations to big family gatherings with a wide variety of foods at the table. One common condition, a…
Updated Standard of Care Clinical Guidelines Point to Cairn Diagnostics’ Breath Test for Evaluating Gastric Emptying and Diagnosing Gastroparesis Brentwood, Tenn. — September 13, 2023 — Cairn Diagnostics, an innovative leader in providing cutting-edge FDA-approved breath tests intended for routine use in diagnostic medicine, today announced the inclusion of its 13C-Spirulina Gastric Emptying Breath Test…
Cairn Diagnostics Delivers Virtual Administration of its Novel 13C-Spirulina Gastric Emptying Breath Test Brentwood, Tenn. — September 14, 2021 — Cairn Diagnostics, an innovative leader in providing cutting-edge breath tests intended for routine use in diagnostic medicine, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approval of the Company’s 13C-Spirulina…
Brentwood, Tenn. — September 14, 2021 — Cairn Diagnostics, an innovative leader in providing cutting-edge breath tests intended for routine use in diagnostic medicine, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approval of the Company’s 13C-Spirulina Gastric Emptying Breath Test (GEBT) to now include “at home” administration under virtual supervision of Cairn…